Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9RTXM)

• Drug Name: LY3164530 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DM9RTXM

Molecule-Related Drug Atlas

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[5]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[6]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[7]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[8]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[9]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[10]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[11]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[12]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[9]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[13]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[14]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[15]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[16]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[17]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[18]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[19]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[20]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[18]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Modulator	[3]
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Modulator	[3]

References

• [1] ClinicalTrials.gov (NCT02221882) A Study of LY3164530 in Participants With Cancer
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] Clinical pipeline report, company report or official report of Exelixis (2011).
• [6] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [13] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [14] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [15] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [16] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [17] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [19] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [20] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [21] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).